商品敘述：

This case describes the challenges pharmaceutical multinational corporations (MNCs) face in understanding and navigating the intricacies of patent law in India and what they can learn from key pharmaceutical intellectual property (IP) cases being fought in the nation''s courts. Like most emerging markets, India is both an exciting new market opportunity for MNCs and a challenging and complex environment in which to operate. For instance, while the patent protection afforded to products and processes is stringent, at least on paper, its enforcement has often been problematic for MNCs and has thwarted MNCs efforts to operate profitably in India. The case study discusses some of the recent judgments handed down by the Indian courts in high-profile pharmaceutical IP cases (such as Novartis'' Glivec and Bayer''s Nexavar) with a view to helping students formulate strategies to overcome value appropriation problems in India.

涵蓋領域：

Strategy;Barriers to entry;Intellectual property;International business

相關資料：

Case Teaching Note, (ISB052), 9p, by Mridula Anand, Anand Nandkumar

哪些人也有訂購？